OPTIMIST-2 trial will enroll cirrhotic G1patients who will receive OLYSIO and SOVALDI for 12 weeks. #HCV #SOVALDI #OLYSIO

New US package insert for #Olysio including label for #sovaldi combo #hcv https://www.olysio.com/shared/product/olysio/prescribing-information.pdf

Market share of #olysio dependent on payer willingness to cover it with #solvaldi. #Q80K testing for #HCV GT1a "not recommended" with combo

@DonaldJensenMD "HCV-TARGET data on #sovaldi"/hashtag/sovaldi" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#sovaldi combos. GT1 SVR4 85% (70%cirrhosis/90%no).#sovaldi/#olysio+-RBV SVR4 89%(c87%/no92%) #Liver14

Dr. Dietrich presents TRIO SVR12 data. Again, some SVR increment with #sovaldi/#olysio in pre-#harvoni data #Liver14 http://t.co/bSVM6kCsvV

Updated #AASLD/#IDSA guidance has #Viekira Pak, #harvoni and #olysio/harvoni regimens as first line meds for #HCV GT1 http://www.hcvguidelines.org

Though shorter #HCV treatment duration is desirable, side effects & cure rate of #harvoni #viekira and #olysio are not the issue. ACCESS is!

@regulusRx initiated #HCV phase 2 studies for RG-101 in combination with #harvoni #daklinza and #olysio with interim data by end of year

New #HCV black box warning for #HBV reactivation affects #harvoni #epclusa #viekira #zepatier #daklinza #sovaldi #olysio #technivie

Skyrizi Olysio Toilet